Therapeutic Genes for Anti-HIV/AIDS Gene Therapy

Author(s): Chiara Bovolenta, Simona Porcellini, Luca Alberici.

Journal Name: Current Pharmaceutical Biotechnology

Volume 14 , Issue 5 , 2013

Become EABM
Become Reviewer

Abstract:

The multiple therapeutic approaches developed so far to cope HIV-1 infection, such as anti-retroviral drugs, germicides and several attempts of therapeutic vaccination have provided significant amelioration in terms of life-quality and survival rate of AIDS patients. Nevertheless, no approach has demonstrated efficacy in eradicating this lethal, if untreated, infection. The curative power of gene therapy has been proven for the treatment of monogenic immunodeficiensies, where permanent gene modification of host cells is sufficient to correct the defect for life-time. No doubt, a similar concept is not applicable for gene therapy of infectious immunodeficiensies as AIDS, where there is not a single gene to be corrected; rather engineered cells must gain immunotherapeutic or antiviral features to grant either short- or long-term efficacy mostly by acquisition of antiviral genes or payloads. Anti-HIV/AIDS gene therapy is one of the most promising strategy, although challenging, to eradicate HIV-1 infection. In fact, genetic modification of hematopoietic stem cells with one or multiple therapeutic genes is expected to originate blood cell progenies resistant to viral infection and thereby able to prevail on infected unprotected cells. Ultimately, protected cells will re-establish a functional immune system able to control HIV-1 replication. More than hundred gene therapy clinical trials against AIDS employing different viral vectors and transgenes have been approved or are currently ongoing worldwide. This review will overview anti-HIV-1 infection gene therapy field evaluating strength and weakness of the transgenes and payloads used in the past and of those potentially exploitable in the future.

Keywords: AIDS, Chim3, Dominant negative mutant, Entry inhibitors, Gene therapy, HIV, RNA payloads, Viral vectors.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 5
Year: 2013
Page: [488 - 500]
Pages: 13
DOI: 10.2174/138920101405131111104009
Price: $58

Article Metrics

PDF: 8